Physician profile
Anna Beth Brooks
NPI 1891166450
$1,234.94
in general payments reported to CMS, 2019-2025
21 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $85.88 · 2023: $387 · 2024: $346 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003 · Education: $15.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.36 |
| Education | $15.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $367.29 | 2023-2025 | Repatha, Repatha |
| Abbvie INC. | $193.46 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $106.67 | 2024 | |
| Lilly USA, LLC | $79.55 | 2022-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $56.93 | 2021-2023 | |
| Braeburn INC. | $52.90 | 2023-2024 | Brixadi |
| Novartis Pharmaceuticals Corporation | $52.83 | 2025 | |
| Adlon Therapeutics L.P. | $35.28 | 2021 | |
| Janssen Pharmaceuticals, INC | $30.29 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.25 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $26.81 | 2024-2025 | Voquezna |
| Supernus Pharmaceuticals, INC. | $26.50 | 2021-2022 | Xyosted |
| Otsuka America Pharmaceutical, INC. | $26.04 | 2024 | Rexulti |
| Indivior INC. | $24.85 | 2025 | Sublocade |
| Janssen Biotech, INC. | $22.60 | 2024 | Simponi Aria |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.33 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $19.36 | 2022 | |
| Halozyme INC | $16.52 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $15.94 | 2022 | |
| Tolmar, INC. | $15.45 | 2023 | |
| Neos Therapeutics, LP | $14.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.